Novo Nordisk’s answer to Eli Lilly’s multi-receptor drugs isn’t a triple agonist — it’s a combination. CagriSema pairs semaglutide with cagrilintide, an amylin analogue, in a single once-weekly injection, and after Novo filed it with the FDA in December 2025 based on the pivotal REDEFINE trial program, it’s worth understanding what this drug actually is and how its numbers stack up against the rest of the field.
Two Hormones, One Shot
Where retatrutide chases efficacy by activating three different receptors on a single molecule, CagriSema takes a combination-therapy approach: semaglutide (the GLP-1 agonist already familiar from Ozempic and Wegovy) paired with cagrilintide, which mimics amylin, a hormone the pancreas releases alongside insulin that helps regulate satiety and gastric emptying through a separate pathway from GLP-1. The theory is that combining two distinct appetite-and-metabolism pathways produces better results than maxing out either one alone — and the REDEFINE data broadly supports that idea.
What REDEFINE Showed
The REDEFINE program includes two pivotal trials. In REDEFINE 1, conducted in adults with obesity or overweight, participants who adhered to treatment lost an average of 22.7% of body weight over 68 weeks, with 60% of adherent participants achieving 20% or greater weight loss. In REDEFINE 2, run in adults with obesity and type 2 diabetes — a population that typically sees smaller GLP-1 results than non-diabetic patients — average weight loss with full adherence was 15.7%. Across both trials, CagriSema outperformed semaglutide alone on both weight loss and blood sugar control, and topline results released in early 2026 showed better glycemic and weight outcomes than either of its two components would be expected to produce individually.
Where It Sits in the Field
At roughly 22.7% weight loss in its lead trial, CagriSema lands in a competitive middle tier — behind retatrutide’s headline numbers and behind the high-dose end of tirzepatide, but ahead of standard-dose semaglutide alone, and achieved through a genuinely different mechanism (hormone combination rather than multi-receptor agonism). For Novo Nordisk, which has watched Eli Lilly’s tirzepatide and retatrutide post larger single-molecule numbers over the past two years, CagriSema is the company’s most direct answer yet — proof that combining existing, well-understood hormones can meaningfully beat semaglutide alone without waiting on a novel multi-receptor molecule to clear trials.
What’s Next
With the FDA filing submitted in December 2025 based on the REDEFINE 1 and REDEFINE 2 data, a regulatory decision is expected later in 2026. If approved, CagriSema would give Novo Nordisk a genuine answer to Lilly’s tirzepatide in the “better than semaglutide alone” category, without requiring patients to switch to an entirely new molecule.
Frequently Asked Questions
Is CagriSema a new drug?
It’s a new combination of two existing, well-studied hormone-based drug classes — semaglutide (GLP-1) and cagrilintide (amylin analogue) — rather than an entirely novel molecule.
How is this different from retatrutide?
Retatrutide is a single molecule that activates three separate hormone receptors (GLP-1, GIP, and glucagon). CagriSema combines two separately dosed hormone pathways (GLP-1 and amylin) into one injection. Different engineering approach to a similar goal.
Is CagriSema approved yet?
No. It was filed with the FDA in December 2025 and remains under regulatory review as of this writing, with a decision expected later in 2026.
This article is for educational purposes only and summarizes publicly available clinical trial and manufacturer information. CagriSema is investigational and not yet FDA-approved. It is not medical advice.